MPND Inhibitors
MPND inhibitors encompass a variety of chemical compounds that act upon different signaling kinases and pathways, each indirectly leading to the reduced activity of MPND through their specific modes of action. Compounds like PP2, Dasatinib, and Bosutinib are known for their ability to inhibit Src family kinases. The inhibition of these kinases decreases the phosphorylation of MPND, which is vital for its activity. Src kinases play a critical role in regulating the activation of many downstream signaling pathways that can influence the function and regulation of proteins like MPND. By decreasing kinase activity, these compounds effectively reduce the functional activity of MPND by preventing its necessary phosphorylation events.
Other inhibitors like Erlotinib, Lapatinib, and Gefitinib target the EGFR family of tyrosine kinases, while Sorafenib and Vandetanib can inhibit the RAF kinases, which are upstream of many signaling pathways including those regulating MPND activity. The EGFR family and RAF kinases are integral to numerous cellular processes, including cell growth and survival, and their inhibition results in decreased activation of downstream pathways crucial for MPND activity. The remaining compounds, such as Sunitinib, Pazopanib, Crizotinib, and Axitinib, inhibit various receptor tyrosine kinases like VEGFR, PDGFR, c-Kit, ALK, and MET, which are involved in signaling pathways that ultimately lead to the phosphorylation and activation of MPND.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Src family kinase inhibitor that blocks Src kinase activity, leading to reduced phosphorylation of downstream targets involved in cell survival and proliferation pathways. Inhibition of Src kinases can decrease the phosphorylation of MPND, resulting in its decreased activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Multitargeted kinase inhibitor that notably inhibits Src kinases and Bcr-Abl. By targeting Src kinases, Dasatinib can reduce the phosphorylation of substrates such as MPND, thereby decreasing its functional activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
EGFR tyrosine kinase inhibitor that prevents autophosphorylation and subsequent activation of downstream signaling cascades. Reduced EGFR signaling can lead to diminished activation of pathways that regulate the activity of MPND. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual tyrosine kinase inhibitor that targets both EGFR and HER2/neu. Inhibition of these receptors leads to reduced activation of downstream signaling pathways which are implicated in the regulation of MPND activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
RAF inhibitor that also inhibits VEGFR and PDGFR. By inhibiting RAF and its downstream MEK/ERK signaling, Sorafenib can indirectly decrease the activation of MPND by preventing its phosphorylation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Receptor tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit, leading to an inhibition of signaling pathways that may regulate the phosphorylation state and activity of MPND. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Selective EGFR inhibitor that blocks kinase activity, leading to reduced activation of downstream signaling pathways that can regulate the activity and phosphorylation status of MPND. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET tyrosine kinases, leading to decreased signal transduction through pathways that contribute to the phosphorylation and activation of MPND. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Inhibits multiple tyrosine kinases including VEGFR, PDGFR, and c-Kit, which can result in diminished phosphorylation and signaling through pathways that activate MPND. | ||||||